Standardized detection of BCR-ABL mRNA and clinical application in patients with chronic myeloid leukemia

doi:10.3969/j.issn.1004-583X.2021.10.004

Abstract

Abstract:

BCR-ABL mRNA is the molecular marker of chronic myeloid leukemia(CML), and tyrosine kinase inhibitors(TKIs) targeting BCR-ABL mRNA has become the basic drug for CML. BCR-ABL mRNA level is the important indicator for evaluation of TKI efficacy. The mutation in ABL tyrosine kinase domain suggests mechanism of TKI resistance, which could guide the treatment strategy such as the selection of next TKIs. Standardized detection of BCR-ABLmRNA is essential for precisely guiding treatment and the guarantee for CML patients to achieve the best curative effects. Standardization is involved in sample type, testing content, laboratory protocol and report ways. This paper explored the standardized detection of quantification and mutation of BCR-ABL and clinical application in CML patients based on recent literature.

Key words: leukemia,myeloid,chronic, fusion proteins,BCR-ABL, receptor protein-tyrosine kinases, standardization

CLC Number:

R733.72

Qin Yazhen. Standardized detection of BCR-ABL mRNA and clinical application in patients with chronic myeloid leukemia[J]. Clinical Focus, 2021, 36(10): 884-888.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.10.004

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I10/884

Figures/Tables 2

References 22

[1]	Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining[J]. Nature, 1973,243(5405):290-293. doi: 10.1038/243290a0 URL
[2]	Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia[J]. Nature, 1983,306(5940):277-280. doi: 10.1038/306277a0 URL
[3]	Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008[J]. J Clin Oncol, 2011,29(18):2514-2520. doi: 10.1200/JCO.2011.34.7146 pmid: 21576640
[4]	Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience[J]. Blood, 2012,119(9):1981-1987. doi: 10.1182/blood-2011-08-358135 pmid: 22228624
[5]	Daley GQ, van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome[J]. Science, 1990,247(4944):824-830. pmid: 2406902
[6]	Melo JV. BCR-ABL gene variants[J]. Baillieres Clin Haematol, 1997,10(2):203-222. doi: 10.1016/S0950-3536(97)80003-0 URL
[7]	Qin YZ, Jiang Q, Jiang H, et al. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre[J]. Br J Haematol, 2018,182(5):693-700. doi: 10.1111/bjh.15453 URL
[8]	Qin YZ, Huang XJ. Molecular detection of BCR-ABL in chronic myeloid leukemia[J]. Methods Mol Biol, 2016,1465:1-15.
[9]	秦亚溱, 主鸿鹄, 黄晓军. 慢性髓性白血病分子监测手册[M]. 北京: 人民卫生出版社, 2013.
[10]	Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia[J]. Leukemia, 2020,34(4):966-984. doi: 10.1038/s41375-020-0776-2 pmid: 32127639
[11]	National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines): Chronic myeloid leukemia[S]. Version 3. 2021.
[12]	中华医学会血液学分会. 慢性髓性白血病中国诊断与治疗指南(2020年版)[J]. 中华血液学杂志, 2020,41(5):353-364.
[13]	Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML[J]. Blood, 2016,128(1):17-23.
[14]	von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study[J]. Lancet, 2002,359(9305):487-491. doi: 10.1016/S0140-6736(02)07679-1 URL
[15]	Hughes TP, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results[J]. Blood, 2006,108(1):28-37.
[16]	Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials[J]. Blood, 2008,112(8):3330-3338. doi: 10.1182/blood-2008-04-150680 pmid: 18684859
[17]	Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe[J]. Leukemia, 2009,23(11):1957-1963. doi: 10.1038/leu.2009.168 pmid: 19710700
[18]	秦亚溱, 林振兴, 岑建农, 等. 用于转换国际标准的BCR-ABL (P210)转录本水平的转换系数多中心确认研究[J]. 中华血液学杂志, 2014,35(2):134-137.
[19]	秦亚溱, 马道新, 王云贵, 等. 转换国际标准化的 BCR-ABL(P210)转录本水平的转换系数多中心再确认研究[J]. 中华血液学杂志, 2015,36(10):814-817.
[20]	中华医学会血液学分会实验诊断学组, 中国医师协会中国慢性髓性白血病联盟. BCR-ABL酪氨酸激酶区突变检测实验室规范中国专家共识(2015 年版)[J]. 中华血液学杂志, 2015,36(11):899-901.
[21]	Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics[J]. Br J Haematol, 1999,107(3):587-599. doi: 10.1046/j.1365-2141.1999.01749.x URL
[22]	Jiang Q, Zhao XY, Qin YZ, et al. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia[J]. Am J Hematol, 2012,87(12):1065-1069. doi: 10.1002/ajh.23321 pmid: 22965919

治疗时间	最佳 (%)	警告 (%)	失败 (%)
3个月	≤10	>10	如果在1~3个月确认 >10
6个月	≤1	>1~10	>10
12个月	≤0.1	>0.1~1	>1
之后任何时间	≤0.1	>0.1~1, 丧失≤0.1	>1,耐药型ABL突变,高危附加染色体异常

治疗时间	最佳 (%)	警告 (%)	失败 (%)
3个月	≤10	>10	如果在1~3个月确认 >10
6个月	≤1	>1~10	>10
12个月	≤0.1	>0.1~1	>1
之后任何时间	≤0.1	>0.1~1, 丧失≤0.1	>1,耐药型ABL突变,高危附加染色体异常

反应类型	定义
MMR	BCR-ABL^IS≤0.1%
MR4.0	BCR-ABL^IS≤0.01%
	或BCR-ABL^IS=0同时ABL copies≥10 000
MR4.5	BCR-ABL^IS≤0.0032%
	或BCR-ABL^IS=0同时ABL copies≥32 000
MR5.0	BCR-ABL^IS≤0.001%
	或BCR-ABL^IS=0同时ABL copies≥100 000

反应类型	定义
MMR	BCR-ABL^IS≤0.1%
MR4.0	BCR-ABL^IS≤0.01%
	或BCR-ABL^IS=0同时ABL copies≥10 000
MR4.5	BCR-ABL^IS≤0.0032%
	或BCR-ABL^IS=0同时ABL copies≥32 000
MR5.0	BCR-ABL^IS≤0.001%
	或BCR-ABL^IS=0同时ABL copies≥100 000